Monopar Therapeutics shares technical analysis: Pullback dominates after recent selling

Traders Union
All News
Stocks
Monopar Therapeutics slides 4.38% today

Highlights

MNPR/USD trades below short-term moving averages but stays above medium- and long-term levels, indicating underlying bullish structure.
MACD gives a strong buy signal, but other momentum indicators are mixed or negative, with sellers dominating intraday.
Price fell 4.38% to $80.3, with a projected range of $75.9307 to $84.6693 and a 71% probability of further downside.

Indicator divergence as price faces near-term resistance

On the technical front, MNPR trades below the MA-20, while still holding above the MA-50 and the MA-200. The Ichimoku Kijun sits at $80.525, acting as immediate resistance. The expected trading range in coming sessions is $75.9307 to $84.6693. Momentum signals remain conflicted: MACD gives a strong buy reading, with both CCI and Awesome Oscillator neutral, while RSI signals sell and Stochastic RSI is in oversold territory. ADX is neutral, and negative Bull/Bear Power indicates intraday seller dominance, highlighting divergence among key indicators.

Consolidation expected as bearish sentiment tempers volatility

With bearish intraday sentiment dominating and oscillators mixed, the base case is for MNPR to consolidate within a sideways channel between $75.9307 and $84.6693 in the short term. There is a 29% probability of an upside breakout if prices can reclaim levels above immediate resistance, while a 71% probability favors a further decline below support if selling continues. Volatility is expected to remain moderate in this range until a clear break occurs.

Viktoras Karapetjanc, expert at Traders Union, sees Monopar Therapeutics trading in a consolidation phase with bearish intraday pressure. He notes that news catalysts are absent, so recent price moves reflect mainly technical and sentiment-driven flows. The analyst believes confidence remains mixed, with no fundamental shift to alter the outlook. "If Monopar can reclaim levels above $80.525, bullish momentum could return — but for now, I favor patient accumulation within the $75.9307 to $84.6693 range."

Earlier, analysts noted that Monopar Therapeutics shares were consolidating after a period of heightened volatility, with a focus on key technical levels for near-term direction. The latest developments indicate that the prevailing risk remains skewed to the downside, making a close watch of support near $75.93 essential for traders assessing future momentum.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.